Linda Schild

2.1k total citations
17 papers, 397 citations indexed

About

Linda Schild is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Linda Schild has authored 17 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Neurology, 12 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Linda Schild's work include Neuroblastoma Research and Treatments (17 papers), Cell death mechanisms and regulation (8 papers) and Cancer therapeutics and mechanisms (4 papers). Linda Schild is often cited by papers focused on Neuroblastoma Research and Treatments (17 papers), Cell death mechanisms and regulation (8 papers) and Cancer therapeutics and mechanisms (4 papers). Linda Schild collaborates with scholars based in Netherlands, Australia and Sweden. Linda Schild's co-authors include Jan J. Molenaar, Jan Köster, Rogier Versteeg, Huib N. Caron, Fieke Lamers, Marli E. Ebus, M. Emmy M. Dolman, Ellen M. Westerhout, Danny A. Zwijnenburg and Laurel T. Bate-Eya and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Linda Schild

17 papers receiving 395 citations

Peers

Linda Schild

NEURO

ONCOL

IMMUN

Kai-Oliver Henrich Germany

Wendy Fang United States

Federica Lorenzi United Kingdom

Jody Fromm Longo United States

Peter Stroeken Netherlands

JulieAnn Rader United States

Yingfeng Xia China

Huan-Hsien Kuo Taiwan

Inga Müller Germany

Kai-Oliver Henrich Germany

Linda Schild

361 ×1.3

319 ×1.6

NEURO

135 ×1.1

ONCOL

208 ×1.9

66 ×2.1

IMMUN

Citations per year, relative to Linda Schild Linda Schild (= 1×) peers Kai-Oliver Henrich

Countries citing papers authored by Linda Schild

Since Specialization

Citations

This map shows the geographic impact of Linda Schild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Schild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Schild more than expected).

Fields of papers citing papers by Linda Schild

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Schild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Schild. The network helps show where Linda Schild may publish in the future.

Co-authorship network of co-authors of Linda Schild

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Schild. A scholar is included among the top collaborators of Linda Schild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Schild. Linda Schild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Eleveld, Thomas F., Linda Schild, Lindy K. Alles, et al.. (2023). MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma. Frontiers in Oncology. 13. 1130034–1130034. 6 indexed citations

Schild, Linda, Jennemiek van Arkel, Max M. van Noesel, et al.. (2023). Two opposing gene expression patterns within ATRX aberrant neuroblastoma. PLoS ONE. 18(8). e0289084–e0289084. 3 indexed citations

Keller, Kaylee M., Linda Schild, Selma Eising, et al.. (2023). The potential of PARP as a therapeutic target across pediatric solid malignancies. BMC Cancer. 23(1). 310–310. 7 indexed citations

Keller, Kaylee M., Thomas F. Eleveld, Linda Schild, et al.. (2022). Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma. Frontiers in Oncology. 12. 929123–929123. 5 indexed citations

Bate-Eya, Laurel T., Lindy K. Alles, Linda Schild, et al.. (2021). High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular Cancer Therapeutics. 20(6). 1161–1172. 9 indexed citations

Boogaard, Marlinde L. van den, Rurika Oka, Linda Schild, et al.. (2021). Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. Proceedings of the National Academy of Sciences. 118(36). 17 indexed citations

Kholosy, Waleed M., Marc Derieppe, Yan Su, et al.. (2021). Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. Journal of Personalized Medicine. 11(9). 869–869. 17 indexed citations

Schild, Linda, Kaylee M. Keller, Lindy K. Alles, et al.. (2020). Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. European Journal of Cancer. 142. 1–9. 9 indexed citations

Eleveld, Thomas F., Linda Schild, Jan Köster, et al.. (2018). RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. Cancer Research. 78(21). 6297–6307. 40 indexed citations

10.

Moreno‐Smith, Myrthala, Zaowen Chen, Ling Tao, et al.. (2017). p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research. 23(21). 6629–6639. 20 indexed citations

11.

Bate-Eya, Laurel T., Linda Schild, Jan Köster, et al.. (2016). High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 7(19). 27946–27958. 43 indexed citations

12.

Eleveld, Thomas F., Linda Schild, Marli E. Ebus, et al.. (2016). Abstract A31: Activation of the RAS-MAPK pathway in primary neuroblastoma tumors is associated with poor prognosis. Cancer Research. 76(5_Supplement). A31–A31. 1 indexed citations

13.

Bate-Eya, Laurel T., Marli E. Ebus, Jan Köster, et al.. (2013). Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer. 50(3). 628–637. 44 indexed citations

14.

Lamers, Fieke, Linda Schild, Jan Köster, et al.. (2012). Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer. 12(1). 285–285. 22 indexed citations

15.

Lamers, Fieke, Linda Schild, Marli E. Ebus, et al.. (2012). Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. European Journal of Cancer. 48(16). 3093–3103. 34 indexed citations

16.

Lamers, Fieke, Linda Schild, Jan Köster, et al.. (2011). Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. European Journal of Cancer. 48(5). 763–771. 53 indexed citations

17.

Lamers, Fieke, Linda Schild, Marli E. Ebus, et al.. (2011). Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocrine Related Cancer. 18(6). 657–668. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact